Shares of Bio-Techne Corp. shed 3.71% to $71.83 Wednesday, on what proved to be an all-around dismal trading session for the ...

Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...

Amgen Inc . (NASDAQ:AMGN), a leading biotechnology company with a market capitalization of $151.3 billion, is navigating a ...

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Amgen Inc (AMGN) stock saw a decline, ending the day at $280.3 which represents a decrease of $-2.65 or -0.94% from the prior close of $282.95. The stock opened at $280.13 and touched a low of $279.97 ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

Research from the Tufts Center for the Study of Drug Development’s PACT Consortium shows DCTs encourage higher participation ...